# Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

> **NCT06056804** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** tislelizumab
- **DRUG:** thymalfasin
- **RADIATION:** long-term radiotherapy

## Key facts

- **NCT ID:** NCT06056804
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2024-12-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056804, "Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06056804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*